Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Human Genetics, |
RCV000408454 | SCV000281817 | pathogenic | Severe early-childhood-onset retinal dystrophy | 2016-01-01 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001091616 | SCV001247755 | pathogenic | not provided | 2022-12-01 | criteria provided, single submitter | clinical testing | |
Institute of Medical Genetics and Applied Genomics, |
RCV001091616 | SCV001446888 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001091616 | SCV001583713 | pathogenic | not provided | 2023-11-25 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 9 of the ABCA4 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ABCA4 are known to be pathogenic (PMID: 10958761, 24938718, 25312043, 26780318). This variant is present in population databases (rs765707028, gnomAD 0.004%). Disruption of this splice site has been observed in individual(s) with Stargardt disease (PMID: 19265867, 28118664). ClinVar contains an entry for this variant (Variation ID: 236079). Studies have shown that disruption of this splice site alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 28118664). For these reasons, this variant has been classified as Pathogenic. |